Cancer drug specialist Exelixis (NASDAQ: EXEL) was quite the stock market star on Friday. Following news that it's making a ...

Exelixis, Inc. ( NASDAQ:EXEL ) recently posted some strong earnings, and the market responded positively. We did ...

Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...

Exelixis, Inc. EXEL reported better-than-expected fourth-quarter results. EXEL recorded earnings of 55 cents per share, which ...

Exelixis reported increased revenue and earnings in Q4 2024, driven by strong cabozantinib sales, though competitive ...

Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Exelixis (EXEL) announced final results from the phase 3 CheckMate -9ER pivotal trial evaluating Cabometyx in combination with Opdivo versus ...

Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. See why I ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the Citi 2025 ...

Reports Q4 revenue $566.8M, consensus $563.21M. “Exelixis (EXEL) delivered a strong fourth quarter of 2024, positioning us well to maximize ...

Net income for Q4 2024 increased by 63.7% to $139.9 million from $85.5 million in Q4 2023. Exelixis is targeting 2025 revenue of $2.15 billion to $2.25 billion. Exelixis reported increased revenue ...